Immunovant, Inc. Income Statement

Income Statement Mar2019 Mar2020 Mar2021 Mar2022 Mar2023 Mar2024 Mar2025
Revenue & cost
Revenue -0.62M
Gross Profit -0.62M
Operating items
Research & Development 25.73M47.93M68.60M101.81M160.26M212.93M360.92M
Selling, General & Administrative 2.69M18.15M39.51M54.23M48.02M57.28M77.23M
Other Operating Expenses 10.00M12.50M
Operating Expenses 28.43M66.08M108.12M156.03M218.28M282.71M438.15M
EBIT -28.58M-65.67M-107.79M-156.81M-210.95M-258.77M-412.95M
Non-operating items
Interest & Investment Income 7.58M24.95M24.73M
Other Non Operating Income -0.15M0.41M0.33M-0.78M-0.25M-1.01M0.47M
Non Operating Income -0.15M0.41M0.33M-0.78M-0.25M-1.01M0.47M
Net income details
EBT -28.58M-66.29M-107.79M-156.81M-210.95M-258.77M-412.95M
Tax Provisions 0.02M0.10M-0.36M-0.08M0.01M0.57M0.89M
Profit After Tax -28.60M-66.39M-107.43M-156.73M-210.96M-259.34M-413.84M
Income from Continuing Operations -28.60M-66.39M-107.43M-156.73M-210.96M-259.34M-413.84M
Consolidated Net Income -28.60M-66.39M-107.43M-156.73M-210.96M-259.34M-413.84M
Income towards Parent Company -28.60M-66.39M-107.43M-156.73M-210.96M-259.34M-413.84M
Net Income towards Common Stockholders -28.60M-66.39M-107.43M-156.73M-210.96M-259.34M-413.84M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 12.50M81.81M97.97M116.40M130.25M145.29M169.86M
EBITDA -28.58M-65.67M-107.79M-156.81M-210.95M-258.77M-412.95M
Tax Rate 0.00M0.00M